Dyne Therapeutics, INC Form 4 insider transactions

Richard William Scalzo, SVP, Head of Finance & Admin. at Dyne Therapeutics, reported multiple transactions involving the company's common stock, including sales and option exercises, on March 8 and March 11, 2024.

CEO Joshua Brumm exercised stock options and sold shares of Dyne Therapeutics (DYN) on March 8 and March 11, 2024, according to a Form 4 filing with the SEC.

Oxana Beskrovnaya, Chief Scientific Officer of Dyne Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units.

Dyne Therapeutics CEO Joshua Brumm sold 9,086 shares of common stock on March 7, 2024, to satisfy tax withholding obligations related to vesting restricted stock units.

Oxana Beskrovnaya, Chief Scientific Officer of Dyne Therapeutics, sold 2,373 shares of common stock on March 7, 2024, to satisfy tax withholding obligations related to vesting restricted stock units.

Susanna Gatti High, Chief Operating Officer of Dyne Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units.

Wildon Farwell, Chief Medical Officer of Dyne Therapeutics, sold shares to cover tax obligations and under a pre-arranged 10b5-1 trading plan.

Jonathan McNeill, Chief Business Officer of Dyne Therapeutics, sold 2,434 shares to cover tax obligations related to vesting restricted stock units.

Richard William Scalzo, SVP, Head of Finance & Admin. at Dyne Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units.

Director Jason Rhodes reported sales of Dyne Therapeutics (DYN) common stock on March 1, 2024, executed under pre-arranged Rule 10b5-1 trading plans.

Atlas Venture Opportunity Funds I and II sold shares of Dyne Therapeutics (DYN) at $30.05 per share under pre-arranged Rule 10b5-1 trading plans.

Dyne Therapeutics CEO Joshua Brumm exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Jonathan McNeill, Chief Business Officer of Dyne Therapeutics, reports the sale of common stock and exercise of stock options, according to a recent SEC Form 4 filing.

Richard Scalzo, SVP, Head of Finance & Admin. at Dyne Therapeutics, reported exercising stock options and selling shares of common stock on February 29, 2024, and March 1, 2024, under a pre-arranged 10b5-1 trading plan.

Director Jason Rhodes reports the sale of Dyne Therapeutics (DYN) common stock through multiple transactions executed under pre-arranged Rule 10b5-1 trading plans.

Atlas Venture Funds, a significant shareholder in Dyne Therapeutics, executed multiple sales of common stock between February 26 and February 28, 2024, under pre-arranged Rule 10b5-1 trading plans.

Wildon Farwell, Chief Medical Officer of Dyne Therapeutics, sold 407 shares of common stock at $25 per share on February 28, 2024, according to a Form 4 filing with the SEC.